NC-001

NC-001 was Phase II clinical trial that tested the PaMZ regimen (PA-824 + moxifloxacin + pyrazinamide). The regimen was administered for two weeks. Results found PaMZ could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than existing treatments.

Background:

NC-001 was Phase II clinical trial that tested the PaMZ regimen (PA-824 + moxifloxacin + pyrazinamide). The regimen was administered for two weeks.  Results found PaMZ could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than existing treatments. The results of this trial were published in The Lancet in July of 2012. The trial enrolled 68 patients at two sites in South Africa. The trial also helped to validate the combination-development approach to new TB therapies. NC-001 was funded by the Bill & Melinda Gates Foundation, the United States Agency for International Development, UK Aid, and Irish Aid.

 

Phase 2

Trial Components

Regimens